文献速递血液净化与透析

Taurolidine/肝素封管液降低血透导管相关血流感染:3期随机双盲对照研究

Taurolidine/Heparin Lock Solution and Catheter-Related Bloodstream Infection in Hemodialysis: A Randomized, Double-Blind, Active-Control, Phase 3 Study.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-09-06

LOCK IT-100 是一项多中心、随机、双盲、活性对照3期研究,纳入795例经中心静脉导管维持性血透的肾衰竭成人,比较 taurolidine/肝素(13.5 mg/ml + 1000 units/ml)与肝素(1000 units/ml)封管液预防CRBSI。结果显示 taurolidine/肝素组CRBSI发生率2%(9/397),肝素组8%(32/398),风险显著降低(HR 0.29,95%CI 0.14-0.62,P<0.001),安全性相当。

要点

  • taurolidine/肝素封管液较肝素显著降低CRBSI风险,HR 0.29(95%CI 0.14-0.62)。
  • CRBSI发生率 taurolidine/肝素组2%(9/397)vs 肝素组8%(32/398)。
  • 两组导管移除时间及导管通畅丧失时间无显著差异,安全性相当。

核心结论

  • 在经中心静脉导管行血透的受试者中,taurolidine/肝素封管液较肝素降低CRBSI发生风险,且安全性特征相当。

研究设计与样本

  • LOCK IT-100为随机、双盲、活性对照、多中心3期研究,从美国70个中心纳入经中心静脉导管维持性血透的肾衰竭成人。
  • 受试者按1:1随机接受taurolidine/肝素封管液(taurolidine 13.5 mg/ml + 肝素1000 units/ml)或肝素对照封管液(1000 units/ml)。

主要发现

  • 全分析人群N=795中,taurolidine/肝素组CRBSI 9例(n=397,2%),肝素组32例(n=398,8%)。
  • 每1000导管日事件率分别为0.13和0.46,CRBSI时间差异有统计学意义, favoring taurolidine/肝素(P<0.001)。
  • 风险比HR为0.29(95%CI 0.14-0.62),对应taurolidine/肝素较肝素降低CRBSI风险71%。
  • 两组因任何原因移除导管的时间及导管通畅丧失时间无显著差异。

关键数值与推荐

  • 主要终点为经盲法临床裁定委员会评估的CRBSI时间。
  • 次要终点为因任何原因移除导管和导管通畅丧失。

临床怎么用

  • 对于经中心静脉导管行维持性血透的肾衰竭成人,可考虑使用taurolidine/肝素封管液以降低CRBSI风险。
  • 该研究中taurolidine/肝素封管液安全性特征与肝素相当,大多数治疗中出现的不良事件为轻或中度。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Catheter-related bloodstream infections (CRBSIs) are one of the most prevalent, fatal, and costly complications of hemodialysis with a central venous catheter (CVC). The LOCK IT-100 trial compared the efficacy and safety of a taurolidine/heparin catheter lock solution that combines taurolidine 13.5 mg/ml and heparin (1000 units/ml) versus heparin in preventing CRBSIs in participants receiving hemodialysis via CVC. METHODS: LOCK IT-100 was a randomized, double-blind, active-control, multicenter, phase 3 study that enrolled adults with kidney failure undergoing maintenance hemodialysis via CVC from 70 US sites. Participants were randomized 1:1 to taurolidine/heparin catheter lock solution or heparin control catheter lock solution (1000 units/ml). The primary end point was time to CRBSI as assessed by a blinded Clinical Adjudication Committee. Secondary end points were catheter removal for any reason and loss of catheter patency. On the basis of a prespecified interim analysis, the Data and Safety Monitoring Board recommended terminating the trial early for efficacy with no safety concerns. RESULTS: In the full analysis population ( N =795), nine participants in the taurolidine/heparin arm ( n =397; 2%) and 32 participants in the heparin arm ( n =398; 8%) had a CRBSI. Event rates per 1000 catheter days were 0.13 and 0.46, respectively, with the difference in time to CRBSI being statistically significant, favoring taurolidine/heparin ( P < 0.001). The hazard ratio was 0.29 (95% confidence interval, 0.14 to 0.62), corresponding to a 71% reduction in risk of CRBSIs with taurolidine/heparin versus heparin. There were no significant differences between study arms in time to catheter removal for any reason or loss of catheter patency. The safety of taurolidine/heparin was comparable with that of heparin, and most treatment-emergent adverse events were mild or moderate. CONCLUSIONS: Taurolidine/heparin reduced the risk of developing a CRBSI in study participants receiving hemodialysis via CVC compared with heparin with a comparable safety profile. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection, NCT02651428 .

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Agarwal AK, Roy-Chaudhury P, Mounts P, et al. Taurolidine/Heparin Lock Solution and Catheter-Related Bloodstream Infection in Hemodialysis: A Randomized, Double-Blind, Active-Control, Phase 3 Study. Clin J Am Soc Nephrol. 2023. PMID: 37678222. doi:10.2215/CJN.0000000000000278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。